Prolaris, the first prognostic test that offers a look inside the molecular biology of prostate cancer, is finding the wolf in sheep's clothing
Prolaris was developed to better measure disease aggressiveness by measuring the expression level of genes involved with cell proliferation. Prolaris adds critical information about prostate cancer, and, in conjunction with clinical parameters such as Gleason score and PSA, helps the physician and patient make personalized treatment decisions for prostate cancer.
Released guidelines that recommend hereditary cancer testing for patients that meet the following criteria:1
Increased screening starting at earlier ages is recommended. Additionally, some patients may choose to have preventive surgeries to drastically reduce the risk of developing certain cancers.
Breast Cancer Risk up to 68x the general population.
Prostate Cancer Risk up to 1.5x the general population.
Pancreatic Cancer Risk up to 7x the general population.
Increased risk for Melanoma and Colon Cancer.
Breast Cancer Risk up to 11x the general population.
Ovarian Cancer Risk up to 44x the general population.
Uterine Cancer Risk up to 47x the general population.
Increased risk for Melanoma, Pancreatic Cancer and Colon Cancer.
Evaluate patients with prostate cancer who may be candidates for hereditary cancer testing. This risk assessment questionnaire can be used to help identify patients with a family history of cancer who may be appropriate for testing.
Waiting for results can increase patient anxiety and delay your medical decisions. Myriad believes optimal patient care should include a rapid turnaround-time for test results. Myriad myRisk provides an average turnaround-time of 2-3 weeks.